Prof Gralnek opened the symposium with a clinical case: a 52-year old woman presented with dizziness and explained that she had had bloody stools…

Successful, cost-effective, and efficient management of disease treatment is the driving factor behind many scientific studies, particularly for diseases…

A 54-year-old male with a history of multiple autoimmune arthritides was admitted following a 3-week history of progressive dysphagia with odynophagia…

The inflammatory bowel diseases (IBD) are a group of conditions characterised by chronic, incurable inflammation in the gastrointestinal (GI) tract…

Inflammatory myofibroblastic tumour (IMT) is a rare mesenchymal solid tumour commonly documented in children and young adults, but also found…

The NEUROTRANSMITTER dopamine has been shown, in the latest research, to play a key role in development of the sympathetic nerves of the mouse lung in…

INHALABLE nanoparticles have been shown success in animal models to treat lung cancer. The study, carried out by a team supervised by Professor Dawen Zhao…

Low levels of return on investment in R&D is an issue that has been bubbling beneath the surface of pharmaceutical companies for some time and the situation is coming to a head, threatening the industry’s future

Patient recruitment and retention remain the biggest challenges in clinical studies, it is surely time for industry to trial a new approach.

Learn about the origins of the medical affairs function, how far it’s come and where it may be heading in the future as key proprietor of patient centricity.